#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
Facial nodules and compounded tirzepatide
One case linked facial nodules to compounded tirzepatide, but missing biopsy and cultures leave inflammation, infection and product factors unresolved.
GLP-1 drugs before surgery: what changed
A 2026 surgical review supports risk-based planning for semaglutide and tirzepatide, but it reports no new trial or aspiration rate.
GLP-1 Mental Health Data in Teens
A small chart review found no short-term increase in suicidality screens among adolescents with obesity using liraglutide or semaglutide.
Incretin weight loss in type 1 diabetes
A 70-person study linked liraglutide, semaglutide, or tirzepatide treatment with fat loss, modest lean loss, and stable total-body bone density.
What a tirzepatide COA cannot verify
A COA may describe a tested sample, but it cannot replace FDA approval, licensed pharmacy dispensing, or individual clinical assessment.
Tirzepatide and Work: Survey Findings
A survey of 518 US employees starting tirzepatide found strong support for obesity-drug coverage, but it did not measure treatment effects.
Tirzepatide and Exercise Anaphylaxis
A case report links tirzepatide with exercise-induced anaphylaxis in one patient, with no recurrence after the medicine was stopped.
Tirzepatide in pasireotide hyperglycemia
A new case report found improved glucose measures after tirzepatide in one patient with pasireotide-related hyperglycemia. Here is what it can and cannot show.
Foundayo's $98 million launch quarter
Lilly reported $98 million in Q2 revenue for oral GLP-1 Foundayo. The filing shows an early launch, not proof that the medicine disappointed.
GLP-1 Drugs and Skin Disease Evidence
A 2026 review finds the strongest GLP-1 skin evidence in psoriasis, while most other dermatology uses remain observational.
Do GLP-1 Drugs Affect Muscle and Bone?
A 2026 meta-analysis found a low-certainty lean-mass signal with GLP-1 drugs, but no adjusted effect on bone or joint outcomes.
GLP-1 Weight Loss Depended on AgRP Neurons
A 2026 mouse study found that disrupting AgRP neurons weakened the full weight-lowering response to GLP-1 receptor agonists in females.